faes tech566
TRANSCRIPT
-
8/7/2019 FAES Tech566
1/16
Effect of Healthcare Systems on theGrowth and Development of Biotechnology
Kevin Yang
TECH566
-
8/7/2019 FAES Tech566
2/16
-
8/7/2019 FAES Tech566
3/16
Biotechnology
-
8/7/2019 FAES Tech566
4/16
-
8/7/2019 FAES Tech566
5/16
-
8/7/2019 FAES Tech566
6/16
U S vs. European Model
Address the demand for care for Employers, employees, elderly, disabled, and low income earners
the general public
Funding National, regional, and state governments
Private sector
-
8/7/2019 FAES Tech566
7/16
European (NHS in Great Britain)Started in 1948
3 Basic PrinciplesU niversalityU nitU niformity
GPs serve as the entrance to the health system (besides emergencies)
NHS hospitals enter in contracts with providers for their medical services: thus promoting competition and reduces pricing (generally speaking)
-
8/7/2019 FAES Tech566
8/16
U S healthcare
Based on private insurance without the concept of universal coverage
Public programs funded from taxes (Medicare and Medicaid)
Coverage through voluntary contracts with private insurancecompanies
Most insurance is through employers
Public and private are not mutually exclusive
-
8/7/2019 FAES Tech566
9/16
U S assessment
First in:Total per capital expenditure
Total volume of drug consumption
In share of GDP devoted to health
Spending for private health services
-
8/7/2019 FAES Tech566
10/16
-
8/7/2019 FAES Tech566
11/16
Biotech Innovations in the U S: Benchmark for success
Not as the direct result of the Healthcare system
U S has the largest economy
Largest pharmaceutical market No price controls
Drug patents last 20 years
-
8/7/2019 FAES Tech566
12/16
Favorable Politics inU
SBayh-Dole Act (1980)
Orphan Drug Act (1983)
SBIR funding
Europe No Bayh-Dole equivalent
Orphan Medicinal Products (2000)
-
8/7/2019 FAES Tech566
13/16
U nited States
Home to leading scientists12 Nobel winners medicine were American born scientists (2009 data)
Top medical innovations came from the U SCT scans
ACE inhibitors
MRI
Cultivation of Entrepreneurial spiritFollowing the footsteps of the technology sector
Availability of venture capital (in the nascent days)
-
8/7/2019 FAES Tech566
14/16
Factors Influencing Competitiveness inBiotechnology (OTA)
Financing and tax incentives
Government funding for basic and applied research
Personnel availability and training
Health, safety and environmental regulations
Intellectual property law
U niversity/industry relations
Anti-trust law
International tech transfer, investment, and trade
Targeted public policies in biotechnology
Public perceptions
-
8/7/2019 FAES Tech566
15/16
Conclusions
Healthcare system in itself does not really promote or inhibit
biotechnology innovation
Environment and the government plays a much larger role
Biotechnology is market driven
-
8/7/2019 FAES Tech566
16/16
Sources
David Nexon and Stephen J. U bl. Implications of Health Reform for the MedicalTechnology Industry. Health Affairs, 29, no. 7 (2010): 1325-1329
Aleksandra Torbica and Giulia Cappellaro. U ptake and diffusion of medicaltechnology innovation in Europe: What role for funding and procurement policies? Jou rnal o f Medical Marketing, 10, no. 1 (2009): 61-69
Nicolas Odier. The U S healthcare system: A proposal for reform. Jou rnal o f Medical Marketing, 10, no. 4 (2010): 279-304
IMS Health Prognosis, 2009
Chase-Dunn, Christopher, Lara-Millian, Armando, and Richard Niemeyer. B io techn o l o gy in the Gl ob al P o litical Ec o nom y. Institute for Research on World-Systems. U niversity of California, Riverside: 2004.